Cordova Ashley - Feb 28, 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Financial Officer
Signature
By: /s/ Steven Robbins, Attorney in Fact for Ashley Cordova
Stock symbol
NVCR
Transactions as of
Feb 28, 2023
Transactions value $
$2,881,245
Form type
4
Date filed
3/2/2023, 03:55 PM
Previous filing
Jan 10, 2023
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $0 +23.8K +32% $0.00 98.3K Feb 28, 2023 Direct F1
transaction NVCR Ordinary Shares Sale -$168K -2.2K -2.24% $76.36 96.1K Mar 1, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Options to Buy Ordinary Shares Award $3.05M +39.6K $76.97 39.6K Feb 28, 2023 Ordinary Shares 39.6K $76.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Options to buy 39,614 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.